This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: B21.1 (HIV disease resulting in Burkitt lymphoma) | Special Copayment Reduction: V103 (severe intractable disease, 5 years) |
| B. Synonyms | HIV-associated Burkitt lymphoma; AIDS-related Burkitt lymphoma; Burkitt lymphoma in AIDS; HIV-associated high-grade B-cell lymphoma with MYC rearrangement |
| C. Adult onset | Likelihood of first onset in adulthood: very high — HIV-associated Burkitt lymphoma occurs mainly in adults (20s–50s), and the risk of Burkitt lymphoma in HIV-infected adults is about 10–20 times higher than in the general population. It also occurs in children, but the AIDS-related form is much more common in adults. |
| 1. History | 1958: described by Denis Burkitt in African children. 1972: c-MYC rearrangement discovered. 1983: included as an AIDS-defining opportunistic malignancy. Incidence has not decreased substantially even after ART. |
| 2. Causes | Arises from the combination of HIV-induced B-cell hyperproliferation, chronic antigen stimulation, and c-MYC rearrangement. EBV coinfection is found in some AIDS-related Burkitt lymphoma. Can occur even when CD4 is relatively high. |
| 3. Genetics | The t(8;14)(q24;q32) translocation of the c-MYC gene (or t(2;8), t(8;22)) is the essential molecular marker. MYC-IgH fusion places MYC expression under the control of the immunoglobulin enhancer. Absence of BCL2 rearrangement is characteristic. |
| 4. General epidemiology | AIDS-related Burkitt lymphoma accounts for about 30–40% of non-Hodgkin lymphoma (NHL). Annual incidence in HIV patients about 500–1000/100,000. Incidence has not changed substantially even after ART (immune-independent mechanism). |
| 5. Pathophysiology | HIV chronic antigen stimulation causes B-cell hyperproliferation → c-MYC translocation and aberrant expression → tumorigenesis. Absence of IDH1/2 mutations and absence of BCL2/BCL6 rearrangement are characteristic. Cell cycle dysregulation due to MYC protein overexpression. |
| 6. Symptoms | Rapidly growing abdominal mass (most common presentation), head and neck lymphadenopathy, bone marrow involvement, CNS involvement. B symptoms (fever, night sweats, weight loss). Abdominal pain, bowel obstruction, ascites. Risk of tumor lysis syndrome owing to rapid growth. |
| 7. Signs | Abdominal mass, hepatomegaly, ascites, lymphadenopathy. Markedly elevated LDH, elevated uric acid (tumor lysis), hyperphosphatemia, hypocalcemia, hyperkalemia (in tumor lysis syndrome). Cytopenias. |
| 8. Screening | Suspect lymphoma immediately in HIV patients with rapid lymphadenopathy, abdominal mass, or sharply elevated LDH. Include weight and lymph node examination at annual routine HIV visits. |
| 9. Diagnosis | Tissue biopsy (morphology, immunophenotype, and cytogenetics essential). FISH to confirm MYC rearrangement. CD10+, BCL6+, BCL2-, Ki-67 >95%. Staging by PET-CT. Lumbar puncture for CNS assessment. |
| 10. Treatment | High-intensity chemotherapy (R-CODOX-M/IVAC, SC-EPOCH-R, etc.). Concurrent ART and management of drug interactions. CNS prophylaxis with intrathecal injection (methotrexate). Prevention of tumor lysis syndrome (allopurinol, rasburicase, hydration). |
| 11. Prognosis | Prognosis was very poor in the pre-ART era. In the era of ART + high-intensity chemotherapy, a complete remission rate of 50–60% and a 2-year survival of about 50–70% have been reported. Performance status, bone marrow/CNS involvement, and CD4 count are the determinants of prognosis. |
| 12. Prevention | Maintain HIV suppression with ART. There is still no prevention specific to Burkitt lymphoma. Monitoring of EBV-related HIV complications. |
| 13. References | Dunleavy K et al. NEJM 2013 and 9 other articles |
Burkitt lymphoma was first described in 1958, when the British surgeon Denis Parsons Burkitt reported, in Uganda, Africa, characteristic clinical features in children, including tumors of the jaw and abdominal tumors. Burkitt observed that this tumor occurs intensively in particular climatic regions of tropical Africa and that its geographic distribution coincides with malaria-endemic areas, and proposed an association with malaria. This "African endemic form (endemic Burkitt lymphoma)" was subsequently established as a lymphoma with distinctive sites of presentation (jaw bone, abdominal viscera), epidemiological distribution, and prognostic characteristics.
In 1964, Michael Anthony Epstein and Yvonne Barr discovered a new herpesvirus in Burkitt lymphoma cells, which was named the Epstein-Barr virus (EBV). This was the first case in which a virus was found in a human cancer and became a milestone in tumor virology. EBV is detected in about 95% of African endemic Burkitt lymphoma.
In 1972, a translocation between chromosome 8 carrying the c-MYC gene and chromosome 14 carrying the immunoglobulin heavy chain gene — t(8;14) — was discovered in Burkitt lymphoma. This MYC rearrangement later became central to the molecular definition of Burkitt lymphoma. The "sporadic" form of Burkitt lymphoma, which occurs in immunocompetent individuals, is more common in the West and has a low EBV association (about 20–30%).
From the early AIDS epidemic in 1981–1982, an increase in high-grade B-cell lymphomas including Burkitt lymphoma in HIV-infected people was reported. In 1985 the CDC included confirmed Burkitt lymphoma in HIV patients among AIDS-defining illnesses. Unlike the sporadic form, AIDS-related Burkitt lymphoma has a low EBV association (about 30–40%) and can occur even with relatively high CD4 counts (200–500/μL), suggesting a pathogenesis less dependent on immune status.
After the introduction of ART in 1996, the incidence of AIDS-related DLBCL and primary effusion lymphoma declined greatly, whereas the incidence of Burkitt lymphoma did not change substantially. This suggests that HIV-related B-cell hyperproliferation and chronic antigen stimulation, independent of CD4 count, are more involved in the pathogenesis of Burkitt lymphoma. In terms of treatment, advances in high-intensity chemotherapy (CODOX-M/IVAC, R-CODOX-M/IVAC, SC-EPOCH-R) and concurrent ART have greatly improved the prognosis of patients with AIDS-related Burkitt lymphoma.
The development of AIDS-related Burkitt lymphoma is contributed to in combination by immune dysregulation and B-cell hyperproliferation due to HIV infection, c-MYC gene translocation, and EBV coinfection (in some).
HIV destroys CD4+ T cells while simultaneously causing chronic immune activation and B-cell hyperproliferation. HIV itself affects B cells directly, or dysregulation of CD4+ T cell help due to HIV infection promotes uncontrolled B-cell proliferation and increased somatic hypermutation. Increased germinal center reactions from chronic antigen stimulation (HIV antigens, EBV antigens, antigens of other pathogens) raise the risk of c-MYC translocation.
The molecular hallmark of Burkitt lymphoma is translocation between the c-MYC gene (8q24) and an immunoglobulin gene (mainly IgH/14q32, or IgL κ/2p12, IgL λ/22q11). t(8;14)(q24;q32) accounts for about 80%, and t(2;8) and t(8;22) occur in the remaining 20%. With this translocation, c-MYC expression comes under the control of the immunoglobulin gene enhancer, resulting in sustained, high-level expression; cell cycle entry, DNA replication, and protein synthesis increase sharply, causing very rapid cell proliferation (Ki-67 nearly 100%).
EBV association in AIDS-related Burkitt lymphoma is about 30–40%, somewhat higher than the sporadic form but lower than the African endemic form. The EBV EBNA-1 protein can increase the activity of the AID (Activation-Induced cytidine Deaminase) enzyme that causes MYC translocation and raises the likelihood of MYC translocation in germinal center B cells.
The genetic hallmark of Burkitt lymphoma is that c-MYC rearrangement is an essential element. c-MYC is a proto-oncogene encoding a transcription factor involved in regulating cell growth, differentiation, proliferation, and apoptosis. In Burkitt lymphoma, MYC protein overexpression due to MYC translocation induces sustained cell cycle activation.
Burkitt lymphoma is characterized by the absence of BCL2 rearrangement (whereas BCL2 rearrangement is commonly present in DLBCL). The immunophenotype is characterized by B-cell markers (CD20+, CD19+, CD10+, BCL6+), BCL2 negativity, and a Ki-67 proliferation index >95%. p53 (TP53) mutations are found in about 40% of AIDS-related Burkitt lymphoma and are more common especially in the sporadic form. Mutations of the ID3 gene (about 67% in the sporadic form) and TCF3 mutations have been shown to contribute to the development of Burkitt lymphoma. CCND3 (cyclin D3) mutations are also found in some Burkitt lymphoma. In whole-genome analysis, Burkitt lymphoma shows a distinct gene expression pattern different from DLBCL, suggesting a germinal center B-cell origin.
The risk of Burkitt lymphoma in HIV-infected people is about 10–20 times higher than in the general population. Among AIDS-related non-Hodgkin lymphoma (NHL), Burkitt lymphoma accounts for about 30–40% and is a major type together with diffuse large B-cell lymphoma (DLBCL, about 40%). Primary effusion lymphoma (PEL) and primary central nervous system lymphoma (PCNSL) are also included in HIV-related NHL.
AIDS-related Burkitt lymphoma tends to occur in patients with relatively high CD4 counts (median about 200–500/μL), distinguishing it from other AIDS-related malignancies. This suggests that MYC translocation can occur at an immune level at which germinal center reactions can occur sufficiently. After the introduction of ART, the overall incidence of AIDS-related NHL decreased, but the decline in Burkitt lymphoma was smaller than for DLBCL. This reflects that Burkitt lymphoma occurs less dependently on CD4 count. It is more frequent in men than in women, and the median age at diagnosis is about 30s–40s.
B-cell abnormal proliferation due to chronic HIV infection provides the soil for c-MYC translocation. HIV gp120 can induce B-cell activation by indirectly interacting with the B-cell CD21 coreceptor, and chronic HIV viremia acts as a persistent nonspecific B-cell stimulus. When germinal center reactions increase, the activity of the AID (Activation-Induced Cytidine Deaminase) enzyme, which catalyzes somatic hypermutation, rises. AID can induce abnormal mutations and translocations not only in immunoglobulin genes but also in cancer-related genes such as c-MYC and BCL6. When MYC-IgH translocation occurs, MYC protein is persistently expressed at high levels by the IgH gene enhancer, promoting the G1/S transition of the cell cycle and explosively increasing cell proliferation. MYC protein activates thousands of genes related to cell proliferation and alters metabolic programming (Warburg effect, aerobic glycolysis) to supply the energy and biosynthetic products needed for rapid cell proliferation.
AIDS-related Burkitt lymphoma is characterized by very rapid tumor growth, and the time from symptom onset to diagnosis is often short, within weeks. Symptoms differ depending on the main site of clinical presentation. Abdominal involvement (most common): rapidly growing abdominal mass, abdominal pain, abdominal distension, nausea and vomiting, ascites. With small bowel or cecal involvement, symptoms of bowel obstruction (acute abdomen) may appear. Head and neck lymphadenopathy: rapidly growing enlargement of cervical, submandibular, and submental lymph nodes. Jaw involvement is relatively rare in HIV-related Burkitt lymphoma (common in the African endemic form). Bone marrow involvement: anemia, thrombocytopenia (bruising, bleeding), leukopenia. Lymphoma cells appear in peripheral blood (lymphoma leukemic conversion). CNS involvement (about 15–30%): headache, cranial nerve palsies, symptoms of increased intracranial pressure. B symptoms: unexplained fever, night sweats, weight loss of 10% or more within 6 months. Tumor lysis syndrome (TLS): may occur immediately after starting chemotherapy or spontaneously, accompanied by hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia, and renal failure.
Physical findings include an abdominal mass (a palpable firm mass), hepatomegaly and splenomegaly, ascites, and cervical, axillary, and inguinal lymphadenopathy. Signs of peritoneal irritation (with peritoneal metastasis) and bowel obstruction may be present. As a laboratory finding, a marked elevation of LDH (lactate dehydrogenase) is characteristic of Burkitt lymphoma (reflecting tumor burden). Elevated uric acid, hyperphosphatemia, and hypocalcemia may appear as precursor findings of TLS. Cytopenias (anemia, thrombocytopenia, leukopenia) suggest bone marrow involvement. Elevated β2-microglobulin is used as a prognostic indicator.
Lymphoma (especially Burkitt lymphoma) should be suspected immediately when rapidly growing lymphadenopathy, an abdominal mass, or a sharp rise in LDH is found in an HIV patient. The time from symptom onset to diagnosis must be short; with delay, the tumor can grow several-fold and there is a risk of spontaneous TLS. At routine HIV visits, lymph node palpation, abdominal examination, and blood tests including LDH are recommended. Whole-body PET-CT should be performed promptly for initial staging when non-Hodgkin lymphoma is clinically suspected.
Definitive diagnosis of Burkitt lymphoma is by integrated analysis of tissue biopsy morphology, immunophenotype, and cytogenetics. On tissue biopsy, diffuse proliferation of uniform small- to medium-sized B cells, multiple nucleoli within the nuclei, a high mitotic index, and a "starry sky pattern" (apoptotic cells cleared by phagocytes, with macrophages distributed among them) are characteristic. Immunophenotype: CD20+, CD19+, CD79a+, CD10+, BCL6+, BCL2-, Ki-67 >95% (nearly 100%). Confirmation of MYC rearrangement by FISH (fluorescence in situ hybridization) is essential. EBV association is confirmed by EBV EBER ISH (in situ hybridization). For staging, PET-CT, bone marrow biopsy, and lumbar puncture (CSF cytology, flow cytometry, cytospin smear) are performed.
Treatment of AIDS-related Burkitt lymphoma is based on high-intensity combination chemotherapy, given together with ART. High-intensity regimens are applied if performance status and overall function permit. CODOX-M/IVAC ± rituximab (R-CODOX-M/IVAC): an intensive regimen alternating cyclophosphamide-vincristine-doxorubicin-methotrexate/ifosfamide-etoposide-cytarabine. SC-EPOCH-R (short course, dose-adjusted EPOCH-R): etoposide-prednisolone-vincristine-cyclophosphamide-doxorubicin + rituximab. A relatively less toxic alternative in HIV patients with poor performance status or many complications. In all regimens, CNS prophylaxis: intrathecal methotrexate (± cytarabine and dexamethasone) is essential. Rituximab (anti-CD20 monoclonal antibody) improves survival in CD20+ Burkitt lymphoma. TLS prevention is essential before chemotherapy: hydration (3 L/m²/day or more), allopurinol or rasburicase (urate oxidase), electrolyte correction, and monitoring of renal function. ART is continued during chemotherapy as well, with attention to drug interactions (especially metabolism of vincristine and cyclophosphamide with ritonavir-based PIs).
In the pre-ART era, the prognosis of AIDS-related Burkitt lymphoma was very poor, with a median survival of only a few months. In the era of ART + high-intensity chemotherapy, improvement to a complete remission (CR) rate of about 50–70% and a 2-year overall survival of about 50–70% has been reported. Known poor prognostic factors are pre-treatment performance status (ECOG >2), advanced stage (Ann Arbor III/IV), bone marrow or CNS involvement, markedly elevated LDH, CD4 <100/μL, and age >60 years. The higher the International Prognostic Index (IPI) score, the worse the prognosis. Chemotherapy toxicity (myelosuppression, infection) is more severe in HIV patients, so treatment-related mortality is higher than in immunocompetent people.
There is currently no direct prevention for AIDS-related Burkitt lymphoma. Suppressing HIV with ART and preserving CD4 reduce the overall risk of AIDS-related lymphoma, but Burkitt lymphoma is less dependent on CD4, so ART alone does not sufficiently prevent it. For EBV-related AIDS complications, EBV viral load monitoring has been attempted in some high-risk HIV patients, but there is not yet an established application for preventing Burkitt lymphoma. A realistic approach is to focus on early detection of lymphoma in HIV-infected patients through regular clinical visits and tests such as LDH and blood counts.
Dunleavy K, Pittaluga S, Maeda LS, et al. SC-EPOCH-RR intensive chemotherapy is safe and effective in adults with Burkitt lymphoma: a prospective study of 17 new agents. Blood. 2013;122(7):1246-1252. DOI: 10.1182/blood-2013-02-485045. PMID: 23821657.
Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC, with and without rituximab, in mature B-cell neoplasms (Burkitt lymphoma, Burkitt-like lymphoma and other high-grade B-cell lymphoma). Ann Oncol. 2008;19(8):1419-1424. DOI: 10.1093/annonc/mdn118. PMID: 18453514.
Robak T, Blonski JZ, Kasznicki M, et al. Burkitt's lymphoma and leukemia in immunosuppressed patients. Leuk Lymphoma. 2001;42(6):1147-1158. DOI: 10.3109/10428190109097743. PMID: 11911408.
Lim ST, Karim R, Tulpule A, et al. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy. J Clin Oncol. 2005;23(33):8477-8482. DOI: 10.1200/JCO.2005.02.4968. PMID: 16293870.
Crombie JL, LaCasce AS. The treatment of Burkitt lymphoma in adults. Blood. 2021;137(6):743-750. DOI: 10.1182/blood.2019004099. PMID: 32902646.
Burkitt DP. A sarcoma involving the jaws in African children. Br J Surg. 1958;46(197):218-223. DOI: 10.1002/bjs.18004619704. PMID: 13560162.
Silverberg MJ, Abrams DI. AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. Curr Opin Oncol. 2007;19(5):446-451. DOI: 10.1097/CCO.0b013e3282c8c95d. PMID: 17762573.
Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th ed.). IARC Press. 2017. ISBN: 9789283244943.
Carbone A, Gloghini A. AIDS-related lymphomas: from pathogenesis to pathology. Br J Haematol. 2005;130(5):662-670. DOI: 10.1111/j.1365-2141.2005.05674.x. PMID: 16115119.
Cairo MS, Raetz E, Lim MS, Davenport V, Perkins SL. Childhood and adolescent large-cell lymphoma (LCL): a review of the Children's Cancer Group experience. Am J Hematol. 2003;72(1):53-63. DOI: 10.1002/ajh.10267. PMID: 12508270.